Summary Cell lines resistant to adriamycin and amsacrine were derived from cloned sublines of the human T cell line Jurkat. Most of the lines resemble atypical MDR cells Beck et al., 1987 
Resistance of cancer cells to chemotherapeutic agents may be an inherent property of a tumour, or may develop during the course of treatment, perhaps due to mutagenising effects of drugs used (Shoemaker et al., 1983; Kees, 1987) . Recently observed mechanisms of drug resistance include reduced drug accumulation, altered drug targets, elevated DNA repair and altered metabolism of drugs (Curt et al., 1984) . The (Fairchild et al., 1987) . Amplification of genes encoding Pgp may cause overexpression of the protein, although elevated transcription can precede amplification (Shen et al., 1986) . Analogy with bacterial transport systems suggests that Pgp functions as a membrane transport protein to actively pump drugs from cells (Ames, 1986) .
The term 'atypical MDR' was coined by Danks et al. (1987) to describe cells cross resistant to several topoisomerases inhibiting drugs but sensitive to Vinca alkaloids. Resistance of these human leukaemic cells was not mediated by increased drug efflux, and neither Pgp expression nor mdr transcripts were detected Beck et al., 1987) . In other reports of resistance (Pommier et al., 1986; Per et al., 1987) or hypersensitivity (Robson et al., 1987) to topoisomerase II inhibiting drugs, it has been suggested that quantitatively or qualitatively altered topoisomerase II or a topoisomerase II modifying activity affects the altered production of drug-induced protein-associated DNA breaks observed in such cells.
In this study, clonal sublines of a human leukaemic T cell line (Jurkat) were used to develop in vitro drug resistance to two clinically useful chemotherapy drugs, adriamycin and amsacrine. Properties of resistant and parental drug-sensitive (control) sublines were compared in an attempt to elucidate the mechanism(s) of resistance involved.
Methods

Materials
Cytotoxic drugs were obtained as pharmaceutical preparations, except for amsacrine which was a gift from the Cancer Research Laboratory, University of Auckland School of Medicine. Standard samples of daunorubicin, adriamycin and their metabolic degradation products were generous gifts from Farmitalia Carlo Erba Ltd, Italy. Antisera were produced by immunisation of New Zealand white rabbits with washed intact Jurkat cells (anti-Jurkat), PHA-stimulated human T cells (anti-PBLT) or JL AMSA cells (anti-AMSAR). Non-immune serum (NRS) was obtained from the same rabbits before immunisation.
Selection for drug resistance Clonal Jurkat sublines Bi, B2 and Little (previously characterised by Snow & Judd 1987, now generally referred to as JB1, JB2 and JL) were used to select sublines which could grow in the continuous presence of adriamycin or amsacrine. Using stepwise increases in drug concentrations, between 6 and 10 months was required to obtain sublines resistant to 200 nM adriamycin (JL adria and JB1 adria) or 1 j4M amsacrine (JL AMSA, JB1 AMSA and JB2 AMSA). One subline (JL adria 500) was selected for resistance to 500 nM adriamycin. In some experiments, two or three subcultures of the same subline were assayed separately (e.g. JL control 1, JL control 2, and JL control 3). In every case, control and resistant sublines had been cultured for the same length of time since selection for resistance was initiated. Resistant sublines had growth rates and viabilities equal to those of the corresponding control sublines.
Cytotoxicity assay Between 20 x 104 and 40 x 104 cells per test were incubated with a range of drug concentrations at 37°C for 3 days as 1 ml cultures in 24 well plates before cell density was determined using a haemocytometer. The IC_0 is the drug concentration required to decrease cell density to 50% of that in the untreated culture after incubation for 3 days. The resistance factor (R factor) of a subline is defined as:
IC50 of drug-resistant subline for a particular drug IC50 of control subline
Modulation of drug resistance was tested by comparing ICos (Kessel & Wheeler, 1984) , or minutes (Yanovich & Taub, 1983) (Streeter et al., 1986) . After extraction for I h at 37°C, samples were centrifuged (5 min, 400 g, room temperature) and fluorescence was measured in a Shimadzu model RF-540 spectrofluorophotometer (excitation 495 nm, emission 552 nm). Fluorescence in samples was stable for at least I week. Adriamycin was quantitated from a linear standard curve prepared from the fluorescence of known concentrations of adriamycin. Amsacrine was extracted from drug treated cells by 0.3 M NaOH, 50% ethanol for 3 days at room temperature. Under these conditions, amsacrine hydrolysed to highly fluorescent 9-aminoacridine, reaching approximately 50% conversion after 3 days. Hydrolysis was linear with respect to the initial amsacrine concentrations up to 5 LM. Fluorescence of centrifuged samples was measured using excitation 410 nm, emission 485 nm. Amsacrine was quantitated from standard curves prepared using known amsacrine concentrations incubated in alkaline ethanolic solution over the same time period.
Radioisotope labelling Exponentially growing cells were labelled with 25 laCi ml-' 35S-methionine for between 6 and 14 h in methionine-free culture medium containing dialysed FCS.
LPO-catalysed radioiodination of cell surface proteins was performed as previously described by Snow and Judd (1987) .
Detergent extraction ofproteins
Detergent extraction mixtures contained 0.5-2 x I07 cells ml. 35S-met labelled cells were sequentially extracted by NP40, DOC/Brij 58 then SDS to solubilise progressively more hydrophobic proteins. Washed cells were resuspended in 1 % NP40, 50 mM Tris HCI (pH 6.8), 1 mM PMSF, incubated on ice for 45 min then centrifuged (10 min, 400 g, 4°C) to obtain NP40 extract. Pelleted cells were resuspended in 0.5% sodium deoxycholate (DOC), 1% Brij 58, 10 mM NaCI, bated on ice for 45 min then centrifuged to obtain DOC/Brij extract. Cell pellets were finally resuspended in SDS-PAGE sample buffer without 2-mercaptoethanol at room temperature. Several 5 s sonications were immediately performed (on ice) to shear DNA.
Protein analysis Proteins were separated by SDS-PAGE using 5 to 15% acrylamide gradients. Fluorography of gels was used to visualise radiolabelled proteins.
Analysis of anthracycline metabolism Drug incubations and separation of metabolites by TLC were performed as previously described by others (Ahmed et al., 1978; Ahmed, 1985) . Reaction (Bradford, 1976) .
Cytogenetic analyses Chromosomes were G-banded as previously described (Snow & Judd, 1987) (Kanter & Schwartz, 1982) (Rowe et al., 1986) , cells were washed twice in cold RPMI 1640 then resuspended in RPMI 1640 containing 5% FCS (prewarmed to 37°C) at a density of 105 cells ml. One ml aliquots of cell suspension were placed in wells of 24 well plates which contained adriamycin or amsacrine solutions. After incubation at 37°C, plates were centrifuged and medium aspirated from the wells. Prewarmed (65°C) lysis solution (800 dl) was added to each well and samples were left at room temperature for 5-O min before being transferred to Eppendorf tubes. As soon as 200 il of 325 mM KCI (prewarmed to 37°C) was added, tubes were vortexed vigorously for 10 s. Samples were cooled on ice for 10 min then centrifuged in a microfuge at 4°C for 10 min. Pellets were resuspended in 1 ml of wash solution, deposited on Whatman GF/C filters and filtered by gravity. Filters were then washed three times with wash solution and dried before determining radioactivity in a scintillation counter. Fold stimulation of PDC formation was calculated from: dpm bound to filters from drug-treated samples dpm bound to filters from non-drug-treated samples Lysis solution contained 1.25% SDS, 0.4mgml salmon sperm DNA, 5 mM EDTA, pH 8.0. Wash solution contained 100 mM KCI, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0. Drug-DNA binding assay Binding of adriamycin or amsacrine to DNA was assessed by quenching of Hoechst-33342 fluorescence as previously described (Andersson et al., 1986) . At the wavelengths used to measure Hoechst fluorescence (excitation 355 nm, emission 450nm), no fluorescence was detected from adriamycin or amsacrine at the drug concentrations used in binding experiments.
Cells at a density of 106 cells ml were incubated for 1 h at 37°C in PBS containing 5% FCS and 0.5Lg ml1' Hoechst-33342. After centrifugation and resuspension in fresh prewarmed PBS/FCS, various concentrations of adriamycin or amsacrine were added to aliquots of cell suspension. Hoechst fluorescence was determined after incubation at 37°C.
Results
Cross resistance profiles Stability of resistance in the JL AMSA subline (resistance to 1 ytM AMSA) was tested by growing the subline in drugfree medium for 6 months. Cytotoxicity assays showed that JL AMSA maintained high resistance to amsacrine and moderate resistance to adriamycin (data not shown).
In previous reports, amphotericin (Krishan et al., 1985) , calcium antagonists such as verapamil (Merry et al., 1986) and calmodulin inhibitors such as chlorpromazine (Tsuruo, 1983) have been used to obtain partial reversal of drug resistance. In this study, R factors for amsacrine or adriamycin were unaffected by 10 iLM verapamil, 10 !M chlorpromazine or 5l ml1' amphotericin B (data not shown).
Drug accumulation and retention
Because of different average cell sizes for each of the sublines, drug accumulation data has been calculated using cell volumes (assuming spheroid shape) as well as cell numbers. Average cell diameters were 13, 14, 10 and 12 l.M for JL control subculture 1, JL control subculture 2, JL AMSA and JL adria cells, respectively, giving theoretical cell volumes of 11.6, 14.5, 5.3 and 9.1 x 10-l1, respectively.
Figure la,b shows drug content of cells incubated with 2 ILLM amsacrine for various times, then post-incubated in drug-free medium. For each subline, maximum accumulation occurred after 45 min of incubation, followed by decreases in drug content between the 45-and 90 min time points. Maximum accumulation values were 2.9, 4.1, 2.1, 3.1 moles/cell (x 10-16) or 248, 283, 388, 336 .tM for JL control 1, control 2, AMSA and adria sublines respectively. JL control I had the lowest drug retention which was 59% of drug accumulated after 45 min for a 2 h post-incubation without drug. Although similar profiles were obtained by incubating cells with I M or SYlM amsacrine, a IOYM incubation yielded different results -no plateau or peak accumulation was reached during a 90 min incubation (Figure lc,d) . After 45 min of incubation with amsacrine, intracellular drug levels IC5o of drug resistant subline IC5o of control subline extracted proteins from Little sublines. Although several differences were apparent between sublines, none consistently correlated with drug resistance (data not shown). NP40 extractable iodinated surface proteins revealed numerous differences between sublines (arrows in Figure 2 ). The only consistent resistance-associated difference was increased intensity of a protein at 85K MW, particularly from the three amsacrine resistant sublines and to a lesser extent from JL adria 200 and JB1 adria.
Neither immunoblotting (kindly performed by Dr D.R. Bell) using monoclonal antibody C219 (Kartner et al., 1985) nor silver staining detected any Pgp protein from enriched membrane fractions of JL control, JL AMSA or JL adria cells.
Drug metabolism
Since the glutathione detoxification system is involved in metabolism of adriamycin (Arrick & Nathan, 1984) and amsacrine (Shoemaker et al., 1984) , possible contribution of the system to detoxification of these drugs in resistant and control Jurkat sublines was tested. Assays of GSH content (Akerboom & Sies, 1981) , and activities of GSH transferase (Warholm et al., 1985) , GSH peroxidase (Flohe & Gunzler, 1984), GSH reductase (Carlberg & Mannervik, 1985) and y-glutamylcystein synthetase (Seelig & Meister, 1985) did not reveal any significant differences between JL control, and drug resistant sublines (data not shown). In addition, activities of other putative drug metabolising enzymes, catalase (Aebi, 1984) , superoxide dismutase (Beauchamp & Fridovich, 1971) , NADPH cytochrome P450 reductase (Strobel & Dignam, 1978) , aryl sulphotransferase (Sekura et al., 1981) and xanthine oxidase (Dodion et al., 1987) were not altered in resistant compared with control JL sublines (data not shown). An assay previously used to measure anthracycline reductase activity in human leukaemic and myelocytic cells (Ahmed, 1985) was used to compare metabolism of 3H-DNR by JL control and resistant sublines. Cell homogenates from JL sublines (4 mg ml-') were incubated at pH 8.5 with 2 1LM 3H-DNR in the presence or absence of 0.5 mM NADPH for 4.5 h or 24 h at 37C. Figure 3 shows representative fluorographs obtained after sample processing and TLC. The position of DNR (species I) was identified from direct application of 3H-DNR (samples 17 and 34). After incubation for 4.5 h, a small amount of a more slowly migrating species (species II) was present in all JL cell homogenates with added NADPH (samples 11 to 16, Figure 3) (Preston, 1982) Tables III-V indicates that these conclusions are statistically highly significant).
Quantification of DNA breaks using afluorescence assay In this assay, F values represent the fraction of duplex DNA versus total DNA remaining after treatment of cells with alkali to cause unwinding of DNA at break sites. Figure 4 shows the F values obtained after treatment of JL control, AMSA, and adria with various concentrations of amsacrine for 1 h. F values for untreated cells were probably less than one because of inherent nicks in cellular DNA and a small percentage of dead cells in the culture used. Amsacrine concentrations required to reduce F values to 80% of the nondrug-treated values were 0.12 JAM, 11 AM and 7.5 JAM for JL control, JL AMSA and JL adria sublines, respectively. Adriamycin had an unexpected effect on PDC formation. For each subline, stimulation of PDC formation was less after the 2 h incubation (Figure 7b ) than the 1 h incubation (Figure 7a) . Furthermore, for the drug resistant sublines, fold-stimulation was less than 1, suggesting that adriamycin treatment caused more DNA to pass through the filters. Maximum stimulation of PDC formation in control cells after a 1 h adriamycin treatment was approximately 2.3-fold (Figure 7a ), compared with approximately 18-fold stimulation caused by a 1 h amsacrine treatment (Figure 6 ).
Drug-DNA binding within resistant and control cells
Although drug accumulation and retention were unaltered in resistant compared with control cells, it seemed possible that reduced association of the intercalating drugs with DNA could affect resistance of JL AMSA and JL adria cells to DNA damaging effects.
Hoechst-33342 fluorescence of cell suspensions or calf thymus DNA solutions is stable for several hours at 37°C. Uptake and retention of amsacrine or adriamycin were unaffected by preincubation of cells with Hoechst 33342 (data not shown). Incubation time (Hours) Figure 5 Repair of DNA damage in JL cells previously treated with amsacrine or adriamycin. JL control (A), JL AMSA (-) and JL adria (0) cells were treated for I h with 0.2 JAM, 1O JM and 7 JAM amsacrine, respectively a, or 6 JAM, 18 JAM and 18 JM adriamycin, respectively b. After various post-incubation periods in drug-free PBS/5% FCS, the fluorescence assay was used to assess DNA breakage. The repair ratio was calculated from:
F value of cells + drug F value of cells-drug using cells incubated for identical lengths of time in PBS/5% FCS. For each drug treatment, the mean repair ratio was calculated from two independent experiments, each containing duplicate incubations with each concentration of drug.
Hoechst fluorescence was reduced to 50% of the nonadriamycin-treated values by a 1 h exposure to 1.9, 7.2, 3.2, 4.3 and 1.4 JAM adriamycin for JL control 1, control 2, AMSA and adria cells and DNA, respectively (data not shown). Since resistant values fell between control values, it appears that drug binding did not differ significantly between drug resistant and control cells. In contrast to quenching by amsacrine, adriamycin-induced quenching was irreversible (after reincubation of cells in drug-free medium for 30 min).
Comparisons between DNA damaging and cytotoxic effects of drugs It was noted that resistance to cytogenetic damage by drugs did not reflect the resistance of JL adria and JL AMSA sublines to drug cytotoxicity during 3 day continuous exposures. Thus, the JL AMSA subline appeared less resistant to adriamycin-or amsacrine-induced cytogenetic damage than the Little adria subline, whereas the JL AMSA subline was more resistant to amsacrine than the JL adria subline in the cytotoxicity assay. Because of this discrepancy, growth inhibitory effects of amsacrine and adriamycin were also measured after 1 h incubations of cultures with drug at 37°C, 3H bound to filters using drug treated cells 3H bound to filters using untreated cells Standard deviations were calculated from triplicate samples.
followed by centrifugation and resuspension in drug-free medium for 3 days. those from 3 day continuous exposure cytotoxicity experiments. Most notably, resistance of the JL AMSA subline to adriamycin cytotoxicity was negligible in the 1 h exposure assay. Also, the 1 h cytotoxicity assay did not reflect the relatively greater resistance of the JL adria subline to amsacrine-induced cytogenetic damage compared with the JL AMSA subline.
Since production of H202 during adriamycin metabolism may cause DNA breakage (Goormaghtigh & Ruysschaert, 1984 (Beck, 1987; Moscow & Cowan, 1988; Bradley et al., 1988 (Dalton et al., 1986 Although there was no significant difference between JL resistant and control sublines in amsacrine (or adriamycin) accumulation or retention, Figure 1 does show interesting kinetics of amsacrine accumulation. At lower concentrations of drug (Figure 1) , intracellular amsacrine peaked then decreased whereas at higher drug concentrations intracellular amsacrine did not reach plateau levels during the incubation time and intracellular binding sites were not saturated.
For each of the four JL sublines incubated with 1 g1M to 10 1AM amsacrine for 1 h, intracellular to extracellular drug concentration ratios increased from an average of 162 ± 8 to 343 ± 13. Therefore, Jurkat cells exhibited cooperative sequestration of amsacrine as previously described for L1210 cells incubated with this drug (Zwelling et al., 1982) , and our results are in broad agreement with their postulated model of drug movement. The site of drug sequestration cannot be determined from these experiments but the Hoechst quenching reversal results reinforce Zwelling's suggestion that drug is sequestered apart from DNA. JL control or resistant sublines did not show co-operative sequestration of adriamycin since intracellular to extra-cellular drug concentration ratios steadily decreased with increasing extracellular adriamycin concentrations (between 5 and 20 ,LM).
Comparisons of proteins revealed two protein differences between sublines which consistently correlated with the presence of drug resistance. Firstly, there were changes among small polypeptides (<20K MW) extracted by SDS. Van der Bliek et al. (1986) has detected elevated expression of the 19-20K MW calcium-binding cytosolic protein sorcin in resistant cells. However, since differences between Jurkat sublines were not detected in non-ionic detergent extracts, it is unlikely that differences in our cells involved sorcin.
The second resistance-associated difference was an increased amount of an 85K MW protein from JL AMSA, JBI AMSA, JB2 AMSA, JL adria 200 and JBI adria compared with drug-sensitive sublines, seen only after NP40 extraction of radioiodinated surface proteins (Figure 2) . Recently, Hamada et al. (1988) From a large range of protein comparisons between resistant and control Jurkat sublines (most data not shown here), numerous protein differences occurred which were not consistently associated with drug resistance, but were expressions of phenotypic drift. Hence, it was essential to compare more than one set of control and resistant sublines in deciding which changes were drug resistance-related. A similar comment applies to possible cytogenetic correlates of drug resistance. For instance JL AMSA possessed rep(5;13), rep(7;13) and 2der(3) chromosomes. Comparing this line alone with JL control would have made these translocations appear significant in resistance. However, the other drug resistant lines studies including a subline of JL AMSA named JL AM, showed other aberrations.
Numerous assays for enzyme activities suggested that elevated GSH-related detoxification or altered cytochrome P450 functions did not contribute towards drug resistance of Jurkat sublines. In contrast, MDR MCF 7 human breast cancer cells (selected for doxorubicin resistance) contained elevated GSH transferase, GSH peroxidase, UDP glucuronyltransferase and sulpho-transferase activities, and reduced cytochrome P450 inducibility compared with wild type cells (Cowan et al., 1986; Sinha et al., 1987) . Resistant JL cell homogenates contained less of an NADPH-dependent activity which produced a more slowly migrating species (probably daunorubicinol) from 3H-DNR (Figure 3) . The pH optimum (close to pH 8.5) and NADPH dependence of the activity are consistent with the presence of DNR reductase activity (Ahmed, 1985) . Ahmed suggested that intracellular conversion of daunorubicin to daunorubicinol may favour cell killing since lower lipophilicity of the cytotoxic 13-dihydro derivatives would favour intracellular drug retention. Indeed, in a study of daunorubicin resistant human myelocytic cells (Vasanthakumar & Ahmed, 1986) , it was suggested that decreased DNR reductase activity could contribute towards drug resistance. Thus, selection for adriamycin resistant JL cells may have selected for cells containing less aldo-keto reductase activity. However, it is unclear how selec- (Figure Sb) , and the apparent absence of repair seen here as well as by others (Zwelling et al., 1981; Robson et al., 1987) .
Both drug resistant JL sublines were significantly resistant to stimulation of protein associated DNA breaks by amsacrine compared with the control subline ( Figure 6 ). The JL AMSA subline was more resistant than the JL adria subline, reflecting relative resistances of these sublines to cytotoxic effects of amsacrine. Thus, although the relationship between cytotoxicity and PDC formation is unclear, resistance of JL AMSA and JL adria sublines to amsacrine could at least partially be mediated by resistance to PDC formation. Since amsacrine produces PDCs by interaction with topoisomerase II (Zwelling, 1985) , it seems likely that the drug-topoisomerase-DNA interaction is altered in drug resistant JL sublines. While it is not surprising that drug resistant JL sublines resisted stimulation of PDC formation by adriamycin ( Figure   7a ), it was unexpected that adriamycin treated resistant cells apparently contained fewer PDCs than untreated cells. It was also unusual that a 2 h incubation of resistant or control JL cells with adriamycin apparently gave less stimulation of PDC production than a 1 h incubation (Figure 7) . One explanation is that progressive fragmentation of DNA involving non-protein-associated breaks (perhaps involving free radicals) occurred during the adriamycin treatment. Thus, greater fragmentation of DNA would reduce the amount of radiolabelled DNA in PDC complexes on filters, such that PDC formation seemed lower.
Although in general the results were consistent with the hypothesis that drug resistance is effected by alterations in DNA-topoisomerase II-drug interactions, the data also suggest differences in the mode of action, or resistance to amsacrine and adriamycin between JL AMSA and JL adria.
In all assays, JL adria cells were more resistant to amsacrine than to adriamycin although they were selected for resistance to adriamycin. JL AMSA cells, were more resistant to amsacrine than adriamycin in all assays (Table VI) . Thus, correlations with drugs rather than resistant cell type are observed. This data strongly suggests that adriamycin acts in part by a mechanism that is shared with amsacrine and partly by a distinct mechanism, to which the adriamycin resistant cells remain largely susceptible. Developing resistance to adriamycin was more difficult than to amsacrine. The peculiarities of PDC formation with adriamycin, and the likelihood that the drug causes breaks in DNA apart from those induced by topoisomerase II are consistent with this possibility. Differences in amsacrine and adriamycin binding to DNA as shown by the Hoechst fluorescence quenching experiments have also been outlined.
In addition, Table VI contains several quite striking anomalies. For instance, in the fluorescence assay for DNA damage, JL AMSA was more resistant to adriamycin than JL adria, although JL adria was more resistant to adriamycin than JL AMSA in all other assays. Comparing the relative concentrations of amsacrine and adriamycin required to produce similar levels of cytotoxicity or DNA damage to the JL control subline (Table VI) : in cytotoxic or cytogenetic damage assays, concentrations of amsacrine and adriamycin required to produce similar effects were less than 3-fold different, but amsacrine was approximately 40-fold more potent than adriamycin in producing DNA damage detected by the fluorescence assay. Resistance of JL adria to cytogenetic damage by amsacrine was greater than that of JL AMSA, although JL AMSA was more resistant to amsacrine in all other assays. This resistance was not associated with commensurate resistance to PDC formation, so the effect did not involve topoisomerase II. Since the cells had little resistance to H202, resistance to free radical action was not involved either. One possibility is that amsacrine and adriamycin have other modes of action, not associated with topoisomerase II or free radical action, to which the cells have some resistance. For instance, amsacrine present at high concentration in the sequestration site could affect other cellular processes. The present results suggesting some differences in the details of resistance between JL AMSA and JL adria cells have been reinforced by our recent findings of differences in their patterns of resistance to amsacrine analogues (Finlay et al., 1990) .
